These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 19381758

  • 21. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR.
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract] [Full Text] [Related]

  • 22. Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.
    Jaimes EA.
    Semin Nephrol; 2020 Jan; 40(1):49-58. PubMed ID: 32130966
    [Abstract] [Full Text] [Related]

  • 23. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 Jan; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 24. [Steroid-responsive nephrotic syndrome in IgA nephropathy].
    García Camín RM, Cabezas A, Calero F, Ballarín JA.
    Nefrologia; 2004 Jan; 24 Suppl 3():68-71. PubMed ID: 15219073
    [Abstract] [Full Text] [Related]

  • 25. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
    Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ.
    Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
    [Abstract] [Full Text] [Related]

  • 26. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R.
    Arch Dermatol; 2008 Jun; 144(6):779-82. PubMed ID: 18559769
    [Abstract] [Full Text] [Related]

  • 27. VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
    Ravaud A, Digue L, Trufflandier N, Smith D.
    Ann Oncol; 2010 Feb; 21(2):431-432. PubMed ID: 19945958
    [No Abstract] [Full Text] [Related]

  • 28. Painless acute pancreatitis associated with sorafenib treatment: a case report.
    Kobayashi Y, Kanemitu T, Kamoto A, Satoh M, Mori N, Sekii K, Yoshioka T, Itatani H, Fujimoto T.
    Med Oncol; 2011 Jun; 28(2):463-5. PubMed ID: 20300970
    [Abstract] [Full Text] [Related]

  • 29. [Vascular and renal effects of anti-angiogenic therapy].
    Halimi JM, Azizi M, Bobrie G, Bouché O, Deray G, des Guetz G, Lecomte T, Levy B, Mourad JJ, Nochy D, Oudard S, Rieu P, Sahali D.
    Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
    [Abstract] [Full Text] [Related]

  • 30. [Sorafenib(Nexavar)].
    Miyanaga N, Akaza H.
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):1029-33. PubMed ID: 19542731
    [Abstract] [Full Text] [Related]

  • 31. Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
    Dasanu CA, Alexandrescu DT, Dutcher J.
    South Med J; 2007 Mar; 100(3):328-30. PubMed ID: 17396743
    [Abstract] [Full Text] [Related]

  • 32. Sorafenib in advanced clear-cell renal-cell carcinoma.
    Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group.
    N Engl J Med; 2007 Jan 11; 356(2):125-34. PubMed ID: 17215530
    [Abstract] [Full Text] [Related]

  • 33. Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
    Hasegawa Y, Mita K, Matsubara A, Ohdan H.
    Int J Clin Oncol; 2009 Oct 11; 14(5):465-7. PubMed ID: 19856059
    [Abstract] [Full Text] [Related]

  • 34. Acute pancreatitis associated with sorafenib.
    Li M, Srinivas S.
    South Med J; 2007 Sep 11; 100(9):909-11. PubMed ID: 17902294
    [Abstract] [Full Text] [Related]

  • 35. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 11; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 36. Sorafenib rechalenge in metastatic renal cell carcinoma.
    Porta C, Paglino C, Imarisio I.
    BJU Int; 2012 Sep 11; 110(6 Pt B):E235. PubMed ID: 22332769
    [No Abstract] [Full Text] [Related]

  • 37. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
    Shinsako K, Mizuno T, Terada T, Watanabe J, Kamba T, Nakamura E, Ogawa O, Inui K.
    Int J Clin Oncol; 2010 Oct 11; 15(5):512-4. PubMed ID: 20340037
    [Abstract] [Full Text] [Related]

  • 38. Immunoglobulin A nephropathy with massive paramesangial deposits caused by anti-vascular endothelial growth factor therapy for metastatic rectal cancer: a case report and review of the literature.
    Yahata M, Nakaya I, Sakuma T, Sato H, Aoki S, Soma J.
    BMC Res Notes; 2013 Nov 09; 6():450. PubMed ID: 24207130
    [Abstract] [Full Text] [Related]

  • 39. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Berchem G, Dewilde S, Mahassen P.
    Bull Soc Sci Med Grand Duche Luxemb; 2009 Nov 09; (1):7-9. PubMed ID: 19514172
    [Abstract] [Full Text] [Related]

  • 40. Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
    Cicek D, Kandi B, Dagli FA, Karaoglu A, Haligur BD.
    Clin Drug Investig; 2008 Nov 09; 28(12):803-7. PubMed ID: 18991474
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.